robert pearapril washington trump administration officials seeking ways lower drug costs targeting pharmaceutical companies refuse provide samples products generic drug companies making impossible create inexpensive generic copies brand name medicine dr scott gottlieb commissioner food drug administration said recently drug makers must end shenanigans prevent competing products reaching market generic drug developers need samples brand name drugs show generic copy equivalent original maneuvers brand name drug firms dr gottlieb said frustrate ability generic firms purchase doses branded drug need run studies federal trade commission investigating practice says forestall generic competition potentially preserve brand firm monopoly indefinitely federal officials said focusing anticompetitive practices brand name drug makers impetus vow president trump hold prices set drug companies said getting away murder legislation ensure access drug samples generic drug manufacturers broad support congress senator patrick j leahy democrat vermont left senator mike lee republican utah right similar bill house also diverse backers including representatives peter welch democrat vermont mark meadows republican north carolina chairman conservative house freedom caucus bill generic drug developer could file lawsuit federal court could require brand name drug maker provide samples product generic company commercially reasonable market based terms court could also award damages found drug maker refused sell samples without legitimate business justification brand name drug companies make several arguments legislation first say needed f approved generic drugs last year record number nearly percent prescriptions filled generic medicines suggesting generic manufacturers generally able obtain samples need brand name companies say second say bill would boon trial lawyers giving incentive sue brand name pharmaceutical companies damages could worth sales proposed generic drug finally say legislation could endanger patients generic drug developers might follow strict safety protocols government requires brand name drugs f says additional requirements needed protect patient safety tests show equivalence generic brand name drugs testing typically involves relatively small number human subjects small number doses therefore relatively low level risk agency said time researchers using sophisticated science develop new treatments cures fight physical samples thousand pills sounds mundane huge implications consumers access affordable medicines f says received inquiries generic drug companies unable obtain samples needed show generic product works brand name medicine disputes samples involve drugs costly patients medicare program experienced sharp price increases recent years without generic competition pressure drive costs medications food drug agency said current law said cannot compel brand name drug manufacturer sell samples generic company please verify youre robot clicking box invalid email address please enter must select newsletter subscribe view new york times newsletters congressional budget office estimates legislation would save federal government billion years mainly medicare medicaid health programs would spend less prescription drugs savings consumers private health insurance plans could much greater lawmakers parties pushed legislation included far reaching budget bill signed mr trump february dropped last minute even without action congress generic drug companies say denial drug samples needed testing may violate federal antitrust law tends perpetuate monopoly makers brand name medications typically takes years courts resolve claims mylan generic drug company wants obtain samples develop generic version revlimid brand name cancer medicine sold celgene court hearing newark december jonathan jacobson lawyer mylan told federal district judge revlimid costs patients dying month ill patients world said generics market price would much lower people would live longer celgene said court papers obligation help potential competitor valid business justifications declining sell samples terms demanded mylan moreover celgene said overriding concern safety patients mylan generic drug company said excuse devised safety protocols similar followed celgene secretary health human services alex azar ii repeatedly said drug prices high administration said soon roll whole slate proposals reduce prices mr azar suggested private companies pharmacy benefit managers role negotiating prices drugs part b medicare drugs typically administered infusion injection doctor offices hospital outpatient departments version article appears print april page new york edition headline drug company shenanigans dodge generics come scrutiny order reprints todays paper subscribe interested feedback page tell us think go home page